Summary: In this presentation, our Expert discusses efforts underway at Catalent to accelerate the path to clinic for iPSC-based therapies.

Summary: Scientists are leading a well-funded drive to adapt technology for solid tumors while making the whole process much more economical for patients and payers.

Summary: At Catalent, we implement innovative manufacturing and fill & finish methodologies to accelerate the path to commercial for MSCs and other allogeneic modalities.

Summary: Experts discuss the changing experience from the last quarter of a century in the pathway to patients, and how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing.

Summary: Experts discuss a breadth of analytical methodologies, fill & finish approaches and manufacturing designs to accelerate CAR-T therapies to commercial readiness phase in this on-demand webinar.

Summary: Both cell therapy innovators and manufacturing organizations are employing novel technologies and methodologies to adapt to an accelerated and evolving clinical landscape

Summary: This roundtable is a must-watch for early and late-stage cell therapy innovator companies who are considering a manufacturing partnership.

Summary: CAR-T cell therapies require expertise in process development to successfully scale-up manufacturing. Working with an integrated partner like Catalent gives you the ability to manufacture at clinical and commercial scale efficiently and effectively for both autologous and allogeneic cell therapies.

Summary: Catalent has made significant investments in the cell and gene therapy space with strategic acquisitions and commitment to grow and innovate.

Summary: Catalent has made significant investments in capacity expansions to meet the growing demand of our customers.